149 related articles for article (PubMed ID: 2292349)
41. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
Schall R; Müller FO; Hundt HK; Duursema L; Groenewoud G; Middle MV
Arzneimittelforschung; 1996 Jan; 46(1):41-6. PubMed ID: 8821516
[TBL] [Abstract][Full Text] [Related]
42. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
Madar Z
J Nutr; 1989 Dec; 119(12):2023-9. PubMed ID: 2695605
[TBL] [Abstract][Full Text] [Related]
43. Sucrose malabsorption in man after ingestion of alpha-glucosidehydrolase inhibitor.
Caspary WF
Lancet; 1978 Jun; 1(8076):1231-3. PubMed ID: 77996
[TBL] [Abstract][Full Text] [Related]
44. Effect of miglitol administration to non-insulin-dependent diabetic rats.
Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493
[TBL] [Abstract][Full Text] [Related]
45. The effects of low-dose Bay-m-1099 (Miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats.
Tulp OL; Szepesi B; Michaelis OE; DeBouno JF
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1991; 99(1-2):241-6. PubMed ID: 1675969
[TBL] [Abstract][Full Text] [Related]
46. Influence of acarbose on blood glucose and breath hydrogen after carbohydrate load with sucrose or starch.
Koytchev R; Richter W; Erkent U; Kirkov V; Dimitrova V; Nern A; Kunter U
Arzneimittelforschung; 2009; 59(11):557-63. PubMed ID: 20066964
[TBL] [Abstract][Full Text] [Related]
47. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
Kuboyama N; Hayashi I; Yamaguchi T
Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808
[No Abstract] [Full Text] [Related]
48. The effects of an alpha-glucoside hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method.
Radziuk J; Kemmer F; Morishima T; Berchtold P; Vranic M
Diabetes; 1984 Mar; 33(3):207-13. PubMed ID: 6365657
[TBL] [Abstract][Full Text] [Related]
49. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE
S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090
[TBL] [Abstract][Full Text] [Related]
50. Effect of alpha-glycohydrolase inhibitors (Bay m1099 and Bay o1248) on sucrose metabolism in normal men.
Cauderay M; Tappy L; Temler E; Jéquier E; Hillebrand I; Felber JP
Metabolism; 1986 May; 35(5):472-7. PubMed ID: 3517560
[TBL] [Abstract][Full Text] [Related]
51. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
52. A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Katsilambros N; Philippides P; Toskas A; Protopapas J; Frangaki D; Marangos M; Siskoudis P; Anastasopoulou K; Xefteri H; Hillebrand I
Arzneimittelforschung; 1986 Jul; 36(7):1136-8. PubMed ID: 3533089
[TBL] [Abstract][Full Text] [Related]
53. In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.
Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
Can J Physiol Pharmacol; 1996 Nov; 74(11):1196-203. PubMed ID: 9028577
[TBL] [Abstract][Full Text] [Related]
54. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
Aoki K; Kato H; Terauchi Y
Endocr J; 2007 Dec; 54(6):1009-14. PubMed ID: 18048991
[TBL] [Abstract][Full Text] [Related]
55. A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus.
Kennedy FP; Gerich JE
Clin Pharmacol Ther; 1987 Oct; 42(4):455-8. PubMed ID: 3311550
[TBL] [Abstract][Full Text] [Related]
56. The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.
Hillebrand I; Boehme K; Graefe KH; Wehling K
Klin Wochenschr; 1986 Apr; 64(8):393-6. PubMed ID: 3517475
[TBL] [Abstract][Full Text] [Related]
57. [Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
Blicklé JF; Andres E; Brogard JM
Rev Med Interne; 1999 Aug; 20 Suppl 3():379s-383s. PubMed ID: 10480189
[TBL] [Abstract][Full Text] [Related]
58. Scope and specificity of acarbose in slowing carbohydrate absorption in man.
Jenkins DJ; Taylor RH; Goff DV; Fielden H; Misiewicz JJ; Sarson DL; Bloom SR; Alberti KG
Diabetes; 1981 Nov; 30(11):951-4. PubMed ID: 7028548
[TBL] [Abstract][Full Text] [Related]
59. Ca2+ deficiency, selective alpha-glucosidehydrolase inhibition, and insulin secretion.
Salehi A; Lundquist I
Am J Physiol; 1993 Jul; 265(1 Pt 1):E1-9. PubMed ID: 7687825
[TBL] [Abstract][Full Text] [Related]
60. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
